Menu
Back to Journals » The Application of Clinical Genetics » Volume 3
Pilot study of an association between a common variant in the non-muscle myosin heavy chain 9 (MYH9) gene and type 2 diabetic nephropathy in a Taiwanese population
Authors Hsieh C, Hung Y, Pei D, Kuo S, Lin E
Published 16 March 2010 Volume 2010:3 Pages 17—22
DOI https://doi.org/10.2147/TACG.S8583
Review by Single anonymous peer review
Peer reviewer comments 2
Chang-Hsun Hsieh1, Yi-Jen Hung1, Dee Pei2, Shi-Wen Kuo3, Eugene Lin4
1Division of Endocrinology and Metabolism, Tri-Service General Hospital, Taipei; 2Division of Endocrinology and Metabolism, Cardinal Tien Hospital, Taipei County; 3Division of Endocrinology, Buddhist Xindian Tzu Chi General Hospital, Taipei; 4Vita Genomics Inc., Wugu Shiang, Taipei, Taiwan
Abstract: Nowadays diabetic nephropathy (DN) is the most common cause of end-stage renal disease (ESRD). Recent studies have demonstrated that the myosin, heavy chain 9, non-muscle (MYH9) gene is associated with ESRD in African Americans. In this study, we tested the hypothesis that a common single nucleotide polymorphism rs16996677 in the MYH9 gene may contribute to the etiology of DN in type 2 diabetes (T2D) in a Taiwanese population with T2D. There were 180 T2D patients diagnosed with DN and 178 age- and sex-similar T2D without DN controls. Single locus analyses showed no significant main effects of MYH9 rs16996677 on the risk of DN in T2D. The results suggest that the rs16996677 SNP in MYH9 may not contribute to the risk of DN in T2D in Taiwanese T2D patients.
Keywords: diabetic nephropathy, end-stage renal disease, single nucleotide polymorphisms, type 2 diabetes
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.